Perrigo Company plc (PRGO)

Self-care and OTC medicines maker, 31 countries. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 26, 2026. Ranked 54 of the 104 Healthcare companies read so far, by the share within reach now.

A self-care products maker whose filing states 8,100 employees in 31 countries and nothing by kind of work, so pharmaceutical manufacturing leads by description with a share at toiletries.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 33% at the end of 2027, 40% at the end of 2028, 43% at the end of 2030. By the patterns, the work is about 43% desk work, 14% people work and 43% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 58% of the working time stays with people (conversation, in-person and hands-on work), 35% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

8,100 employees as of December 31, 2025 (stated). Not stated: 31 countries, no count by country; the data service's 59% United States is revenue.

The filing: “Our global workforce consists of approximately 8,100 full-time and part-time employees spread across 31 countries, of which approximately 17.5% were covered by collective agreements as of December 31, 2025.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 8,100 full-time and part-time employees across 31 countries as of December 31, 2025 (8,379 a year earlier), about 17.5% covered by collective agreements.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

7 sentences in the filing name AI. The filing says an inability to leverage emerging technologies such as generative artificial intelligence in time and responsibly could harm its business, and that the adoption of AI may intensify its cybersecurity risks.

• “Our inability to timely and responsibly leverage emerging technologies, including generative artificial intelligence, could result in a material adverse effect on our business, and the use of emerging technologies generally could result in regulatory action, legal liability, operational challenges or reputational harm.”
• “In addition, the rapid evolution and increased adoption of new technologies, such as artificial intelligence, may intensify our cybersecurity risks.”
• “Our inability to timely and responsibly leverage emerging technologies, including generative artificial intelligence, could result in a material adverse effect on our business, and the use of emerging technologies generally could result in regulatory action, legal liability, operational challenges or reputational harm.”
• “Our ability to identify, adopt, and effectively integrate emerging technologies, including generative artificial intelligence ("AI"), into our product development, services, and operations is an important factor in maintaining our competitiveness.”
• “Increased use of AI introduces certain risks, including heightened exposure to cybersecurity threats, data privacy and intellectual property concerns, algorithmic errors or bias leading to flawed outputs or poor decision-making, and increased third-party dependency risks.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20231median 1
• Fiscal 20241median 4
• Fiscal 20257median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The U.S. share is not stated.
• No count by product category: the split between medicines and personal care products is by description (c).

Source: the company's annual report on EDGAR, accession 0001585364-26-000009, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.